DOSSIER · 13F-HR · Q1 2026

TRV GP VI, LLC

$136M in tracked AUM across 3 positions as of Q1 2026.

TG
CIK 0001990716 · last filed Mar 31, 2026
Total AUM
$136M
as of Q1 2026
Holdings
3
positions
Whale Score
69
69
tracked
Activity
no data
changes this Q
AI Analysis · Q1 2026
SEC 13F Filing Analysis: TRV GP VI, LLC
1. Portfolio Overview

The filing for TRV GP VI, LLC reveals a highly specialized, concentrated investment portfolio with a high-risk, high-reward profile typical of venture capital or specialized biotechnology investment vehicles. As of the report date September 30, 2025, the total portfolio value stands at approximately $109.64 million, representing a significant growth of 70.7% from the previous quarter's $64.22 million.

The portfolio is ...

2. Key Holdings

The portfolio is dominated by early-stage to mid-stage biotechnology companies, with the top two positions commanding nearly 99% of the total assets.

Quarter at a glance — Q1 2026

Position-change comparison pending.

No quarter-over-quarter changes available.

Top 10 holdings

By portfolio weight as of Q1 2026.

#HoldingValueSharesWeight
01
SEPN
SEPTERNA, INC.
$101M4.2M74.6%
02
RAPP
RAPPORT THERAPEUTICS, INC.
$30M969K22.4%
03
TNGX
TANGO THERAPEUTICS, INC.
$4M194K3.0%

Filing history

2026Q1Mar 31
$136M 8.7%
3 positionsView →
2025Q4Dec 31
$149M 35.5%
3 positionsView →
2025Q3Sep 30
$110M 70.7%
3 positionsView →
2025Q2Jun 30
$64M 53.0%
4 positionsLocked
2025Q1Mar 31
$42M 64.1%
4 positionsLocked
2024Q4Dec 31
$117M
4 positionsLocked